3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
64
Neoplasm Metastasis
25
Kidney Neoplasms
21
Neoplasms
16
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Prostatic Neoplasms
10
Lung Neoplasms
8
Brain Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Neuroendocrine Tumors
6
Liver Neoplasms
6
Glioblastoma
6
Gastrointestinal Stromal Tumors
6
Carcinoma, Hepatocellular
6
Thyroid Neoplasms
5
Thymoma
5
Small Cell Lung Carcinoma
5
Recurrence
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma
5
Uveal Melanoma
4
Stomach Neoplasms
4
Sarcoma
4
Adenocarcinoma
4
Interventions
Paclitaxel
4
Oxaliplatin
4
Cisplatin
4
Radiotherapy
3
Ocoxin
3
Folfox protocol
3
pembrolizumab
2
camrelizumab
2
apatinib
2
anlotinib
2
Sunitinib
2
Sorafenib
2
Imatinib Mesylate
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Capecitabine
2
Bevacizumab
2
tislelizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
genexol-PM
1
durvalumab
1
donafenib
1
copanlisib
1
atezolizumab
1
alectinib
1
Tretinoin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Digestive System Neoplasms
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled